panitumumab: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
panitumumab: clinical details
Prescribing considerations
- Confirm wild-type KRAS and NRAS status using validated testing before initiation.
- Treatment must be supervised by a clinician experienced in anticancer therapy.
- Assess pulmonary history, dermatological status, ocular disease, contact-lens use and ability to tolerate combination therapy.
- Record the product name and batch number for biological-medicine traceability.
- Give skin-care and sun-protection advice; investigate severe or worsening skin toxicity for secondary infection.
Contraindications and cautions
- Previous severe or life-threatening hypersensitivity to panitumumab or an excipient.
- Interstitial pneumonitis or pulmonary fibrosis.
- Combination with oxaliplatin-containing chemotherapy when RAS is mutant or unknown.
Monitoring
- Magnesium and calcium before, during and after treatment; assess potassium and replace electrolytes when appropriate.
- Skin and soft-tissue toxicity, including infection, cellulitis and necrotising fasciitis.
- New or worsening respiratory symptoms; interrupt treatment while possible interstitial lung disease is investigated.
- Acute or worsening corneal symptoms, with prompt ophthalmology referral.
- Diarrhoea, hydration and renal function when clinically indicated.
- Infusion reactions during administration and possible delayed hypersensitivity afterwards.
Clinical pharmacology
A recombinant fully human IgG2 monoclonal antibody that binds the ligand-binding domain of EGFR. Receptor internalisation and reduced downstream signalling inhibit cell growth and promote apoptosis. Pharmacokinetics are nonlinear because clearance includes target-mediated pathways.
Formulation and product differences
- The selected product is a single-use concentrate for intravenous infusion, not a ready-to-administer solution.
- It requires aseptic dilution with sodium chloride solution and administration through a low-protein-binding in-line filter.
- Do not shake or vigorously agitate the vial; the concentrate may contain removable translucent-to-white protein particles.
- It contains no antimicrobial preservative and is refrigerated, protected from light and not frozen.
panitumumab preparations and strengths
Solution for infusion
Route: Intravenous
Strengths: 20 mg/mL
panitumumab interactions
The cancer team should review all current medicines and planned anticancer combinations.
Bevacizumab-containing chemotherapy
Do not combine with panitumumab because increased toxicity and deaths were observed.
IFL chemotherapy
Avoid the combination because it produced a high incidence of severe diarrhoea.
Oxaliplatin-containing chemotherapy
The combination is contraindicated when the tumour has mutant RAS or its RAS status is unknown.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.